Contagion Live | EMA backs 3-month dapivirine ring for HIV prevention in women
The European Medicines Agency (EMA) issued a positive scientific opinion for a 3-month dapivirine vaginal ring for HIV prevention in women and adolescent girls aged 16 years and older, according to a Population Council announcement. The opinion includes women who are breastfeeding. The ring, developed by the Population Council and its affiliate IPM South Africa, requires replacement only 4 times per year instead of 12.
The opinion came through the EMA’s EU-Medicines for All procedure and provides a pathway toward regulatory applications in African countries. The monthly dapivirine ring received a positive EMA opinion in July 2020 and holds regulatory approval in 12 African countries.
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.